GT200600147A - USE OF VASCULAR ENDOTELIAL GROWTH FACTOR RECEIVER INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL, GENITOURINARY, LYMPOID AND PULMONARY CANCER - Google Patents

USE OF VASCULAR ENDOTELIAL GROWTH FACTOR RECEIVER INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL, GENITOURINARY, LYMPOID AND PULMONARY CANCER

Info

Publication number
GT200600147A
GT200600147A GT200600147A GT200600147A GT200600147A GT 200600147 A GT200600147 A GT 200600147A GT 200600147 A GT200600147 A GT 200600147A GT 200600147 A GT200600147 A GT 200600147A GT 200600147 A GT200600147 A GT 200600147A
Authority
GT
Guatemala
Prior art keywords
gastrointestinal
inhibitors
treatment
lympoid
genitourinary
Prior art date
Application number
GT200600147A
Other languages
Spanish (es)
Inventor
William Berg
David Lebwhol
Andrea Kay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600147A publication Critical patent/GT200600147A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

LA IVENCIÓN SE REFIERE AL USO DE INHIBIDORES DE VEGF-R SOLOS O EN COMBINACIÓN CON QUIMIOTERAPIA PARA EL TRATAMIENTO DE PACIENTES CON CÁNCER GASTROINTESTINAL, GENITOUTERINO, LINFOIDE Y PULMONAR (CÉLULA PEQUEÑA Y CÉLULA NO PEQUEÑA) QUE TIENE ALTOS VALORES DE LDH Y PACIENTES CON CÁNCERES DE ORIGEN DE CRESTA NEURAL QUE TIENEN ALTOS VALORES DE LDH. T2006THE IVENTION REFERS TO THE USE OF VEGF-R INHIBITORS ONLY OR IN COMBINATION WITH CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL, GENITOUTERINE, LINFOID AND PULMONARY CANCER (SMALL CELL AND NON-SMALL CELL VALUE) OF ORIGIN OF NEURAL CREST THAT HAVE HIGH VALUES OF LDH. T2006

GT200600147A 2005-04-13 2006-04-10 USE OF VASCULAR ENDOTELIAL GROWTH FACTOR RECEIVER INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL, GENITOURINARY, LYMPOID AND PULMONARY CANCER GT200600147A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67087005P 2005-04-13 2005-04-13
US68039605P 2005-05-12 2005-05-12

Publications (1)

Publication Number Publication Date
GT200600147A true GT200600147A (en) 2006-11-24

Family

ID=36649704

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600147A GT200600147A (en) 2005-04-13 2006-04-10 USE OF VASCULAR ENDOTELIAL GROWTH FACTOR RECEIVER INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL, GENITOURINARY, LYMPOID AND PULMONARY CANCER

Country Status (6)

Country Link
AR (1) AR053576A1 (en)
GT (1) GT200600147A (en)
PE (1) PE20061361A1 (en)
TW (1) TW200719914A (en)
UY (1) UY29471A1 (en)
WO (1) WO2006113172A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4950519A1 (en) * 1997-02-13 2000-09-01 Novartis Ag PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION

Also Published As

Publication number Publication date
TW200719914A (en) 2007-06-01
WO2006113172A1 (en) 2006-10-26
PE20061361A1 (en) 2007-01-03
AR053576A1 (en) 2007-05-09
UY29471A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
CL2011001215A1 (en) Compounds derived from pyrimidine, tyrosine kinase inhibitors; pharmaceutical compositions comprising them; and its use in the treatment and / or prevention of cancer, inflammatory diseases and autoimmune diseases.
GT200600046A (en) COMBINATION THERAPY
CL2016003014A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) (divisional sol. No. 230-11).
CL2007002062A1 (en) Compounds derived from [1,2,4] triazolo [4,3-a] pyridine, kinase inhibitors; pharmaceutical composition; and its use in the treatment of cancer.
AR082017A1 (en) ANTI-AXL ANTIBODIES (THYROSINE KINASE RECEPTOR) AND METHODS OF USE
MX2011008938A (en) Antibodies to troponin i and methods of use thereof.
CL2009000200A1 (en) Compounds derived from 2,7-naphthyridines-1-one, mediators of syk; pharmaceutical composition; and use in the treatment of inflammatory, respiratory, cellular proliferative or autoimmune disease.
UA99833C2 (en) Pyrimidinyl pyridazinone derivates
TR201907783T4 (en) Benzosulfonamide derivatives, compositions and their use in the prevention of cancer cell metastasis.
WO2011150221A3 (en) Compounds and methods of modulating mitochondrial bioenergetic efficiency through an interaction with atp synthase (complex v) and its subunits
CL2012003026A1 (en) Pharmaceutical composition comprising pioglitazone and linagliptin; preparation procedure; Use in the treatment of type 2 diabetes or obesity.
CL2009000721A1 (en) Combination comprising an isolated anti-igf1r antibody or an antigen-binding fragment thereof in association with leucovorin and 5-fluorouracil, leucovorin or sunitinib optionally associated with another chemotherapeutic agent; and its use for the treatment or prevention of colorectal cancer.
MX2021015825A (en) Stable, aqueous antibody formulations.
CL2008003309A1 (en) Compounds derived from substituted cytosine (= 4-amino-pyrimidin-2-one), modulators of cell cycle checkpoint kinases; pharmaceutical composition; pharmaceutical combination; and its use in treating or slowing the progression of cancer.
CL2012002904A1 (en) Combination or pharmaceutical composition comprising an inhibitor of cell signaling and / or angiogenesis and an aurora kinase inhibitor (aki); pharmaceutical kit that includes it; its use in the treatment of oncological and fibrotic diseases; and substituted indole and pyrimidine compounds.
NO20092146L (en) Use of 3-ALFA-Androstiol, optionally in combination with a 5-HT1A agonist, in the treatment of sexual dysfunction
EA201200934A1 (en) ANTI-TRACT COMBINATIONS OF MEDICINES BASED ON ARTHEMISININE WITH OTHER CHEMOTHERAPEUTIC AGENTS
MX2011006725A (en) Combination of aurora kinase inhibitors and anti-cd20 antibodies.
CL2012000392A1 (en) Use of an afucosylated anti-cd20 antibody with a fucose amount of 60% or less to treat cancer in combination with fludarabine.
DK2129391T3 (en) DIAGNOSTIC PROCEDURE
CL2008003602A1 (en) Compounds derived from triazolotriazines and substituted triazolopyrazines; pharmaceutical composition; and its use in the treatment and / or prophylaxis of hematological disorders.
MX2008008768A (en) Treatment of hiv.
GT200600147A (en) USE OF VASCULAR ENDOTELIAL GROWTH FACTOR RECEIVER INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL, GENITOURINARY, LYMPOID AND PULMONARY CANCER
ES2663096T3 (en) Methods for the treatment of nephrotic syndrome and related conditions
WO2009052379A3 (en) Improved antitumoral treatments